Avoiding medication errors can be even easier if you use these 12 tips.
BLA resubmitted for lebrikizumab to treat AD patients 12 years and up
The resubmission was announced in a first quarter, 2024 earnings news release from Lilly, which expects "regulatory action in the second half of 2024."
Food Insecurity and the Dangers of Infant Formula Dilution
A deep dive into Qbtech's diagnostic ADHD test
A discussion based on an FDA-cleared objective ADHD diagnostic test developed by Qbtech.
Demystifying Infant Formula
FDA accepts sNDA for tapinarof cream, 1% to treat AD in children 2 years and up
A decision from the federal agency is expected in the fourth quarter of 2024.
FDA approves diazepam for seizure clusters in patients 2 to 5 years
With the approval comes the immediate availability of 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses for patients between 2 to 5 years of age.